Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Kent Osborne

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Journal of Clinical Oncology

English

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

Journal of Clinical Oncology

English

Related publications

A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer

Cancer Biotherapy and Radiopharmaceuticals

English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology

English

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

International Journal of Cancer

Cancer Research

Oncology

2017

English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

English

A Phase II, Randomized, Multicenter Study Evaluating the Combination of Lapatinib and Vinorelbine in Women With ErbB2 Overexpressing Metastatic Breast Cancer

Breast Cancer Research and Treatment

Cancer Research

Oncology

2014

English

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Pregnancies During and After Trastuzumab and/or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Analysis From the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) Trials

English

Locoregional Therapy With Α-Emitting Trastuzumab Against Peritoneal Metastasis of Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer in Mice

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by C. Kent Osborne

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

Related publications

A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

A Phase II, Randomized, Multicenter Study Evaluating the Combination of Lapatinib and Vinorelbine in Women With ErbB2 Overexpressing Metastatic Breast Cancer

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Pregnancies During and After Trastuzumab and/or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Analysis From the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) Trials

Locoregional Therapy With Α-Emitting Trastuzumab Against Peritoneal Metastasis of Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer in Mice